Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prexton Therapeutics

mGluR4 compounds for Parkinson’s disease

This article was originally published in Start Up

Executive Summary

Prexton Therapeutics aims to advance the standard of care for Parkinson’s disease by developing a therapeutic that strategically targets metabotropic glutamate receptor 4. It plans to use its lead compound as an add-on therapy to facilitate lower therapeutic doses of L-dopa in order to decrease adverse effects, while maintaining the expected therapeutic level of the treatment.

You may also be interested in...



Parkinson’s Disease: Start-Ups Seek Breakthroughs And Money

Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.

Quartet Medicine Inc.

Quartet Medicine Inc.'s pipeline of novel small-molecule drugs to address chronic pain and inflammation target the tetrahydrobiopterin (BH4) synthesis pathway, a target with genetic and pharmacological links to regulating human disease at the intersection of the peripheral nervous system and the immune system. The start-up thinks its approach has the potential to provide improved efficacy without the side effects associated with existing centrally acting analgesics.

ObsEva SA

Despite many improvements in the last 25 years, there continue to be serious unmet medical needs in the area of reproductive health. ObsEva SA, a clinical-stage biopharmaceutical company based in Geneva, Switzerland, aims to address some of those needs with novel oral drugs for three highly prevalent reproductive health-related challenges: endometriosis, pre-term labor, and repeated implantation failure in women undergoing in vitro fertilization.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092785

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel